Next Article in Journal
The Effect of Sertoli Cells on Xenotransplantation and Allotransplantation of Ventral Mesencephalic Tissue in a Rat Model of Parkinson’s Disease
Next Article in Special Issue
JNK-Dependent cJun Phosphorylation Mitigates TGFβ- and EGF-Induced Pre-Malignant Breast Cancer Cell Invasion by Suppressing AP-1-Mediated Transcriptional Responses
Previous Article in Journal
Increased Adipose Tissue Expression of Interferon Regulatory Factor (IRF)-5 in Obesity: Association with Metabolic Inflammation
Previous Article in Special Issue
ACVR1 Function in Health and Disease

TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019

Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, 31527 Tanta, Egypt
Author to whom correspondence should be addressed.
Academic Editor: Isabel Fabregat
Cells 2019, 8(11), 1419;
Received: 11 October 2019 / Revised: 8 November 2019 / Accepted: 9 November 2019 / Published: 11 November 2019
(This article belongs to the Special Issue TGF-beta/BMP Signaling Pathway)
Liver fibrosis is an advanced liver disease condition, which could progress to cirrhosis and hepatocellular carcinoma. To date, there is no direct approved antifibrotic therapy, and current treatment is mainly the removal of the causative factor. Transforming growth factor (TGF)-β is a master profibrogenic cytokine and a promising target to treat fibrosis. However, TGF-β has broad biological functions and its inhibition induces non-desirable side effects, which override therapeutic benefits. Therefore, understanding the pleiotropic effects of TGF-β and its upstream and downstream regulatory mechanisms will help to design better TGF-β based therapeutics. Here, we summarize recent discoveries and milestones on the TGF-β signaling pathway related to liver fibrosis and hepatic stellate cell (HSC) activation, emphasizing research of the last five years. This comprises impact of TGF-β on liver fibrogenesis related biological processes, such as senescence, metabolism, reactive oxygen species generation, epigenetics, circadian rhythm, epithelial mesenchymal transition, and endothelial-mesenchymal transition. We also describe the influence of the microenvironment on the response of HSC to TGF-β. Finally, we discuss new approaches to target the TGF-β pathway, name current clinical trials, and explain promises and drawbacks that deserve to be adequately addressed. View Full-Text
Keywords: TGF-β; liver fibrosis; hepatic stellate cells; myofibroblasts TGF-β; liver fibrosis; hepatic stellate cells; myofibroblasts
Show Figures

Figure 1

MDPI and ACS Style

Dewidar, B.; Meyer, C.; Dooley, S.; Meindl-Beinker, a.N. TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019. Cells 2019, 8, 1419.

AMA Style

Dewidar B, Meyer C, Dooley S, Meindl-Beinker aN. TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019. Cells. 2019; 8(11):1419.

Chicago/Turabian Style

Dewidar, Bedair, Christoph Meyer, Steven Dooley, and and Nadja Meindl-Beinker. 2019. "TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019" Cells 8, no. 11: 1419.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop